Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of -586.74% is 537% below its 3-year average of -92.15%, near the high end of its 3-year range (-2260.45%–0.00%).
46.24% above its 12-month average of -1091.31%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): -581.81%.
NET PROFIT MARGIN
-586.74%
NET PROFIT MARGIN AVG TTM
-1091.31%
NET PROFIT MARGIN AVG 3Y
-92.15%
NET PROFIT MARGIN AVG 5Y
0.00%
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+46.24%
CURRENT VS 3Y AVG
-536.72%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-0.26%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-225569.23%
vs the sector median at left
LENZ Therapeutics, Inc.
Market Cap
$118.83M
Net Profit Margin
-586.74%
TTM Avg
-1091.31%
3Y Avg
-92.15%
5Y Avg
0.00%
Market Cap
$118.59M
Net Profit Margin
-7723.97%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$119.84M
Net Profit Margin
-2258.89%
TTM Avg
-4695.34%
3Y Avg
-8719.58%
5Y Avg
-5863.11%
Market Cap
$117.76M
Net Profit Margin
0.00%
TTM Avg
-539.97%
3Y Avg
-388.73%
5Y Avg
-259.15%
Market Cap
$120.41M
Net Profit Margin
-490.71%
TTM Avg
-538.75%
3Y Avg
-569.71%
5Y Avg
-1398.02%
Market Cap
$120.58M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$116.76M
Net Profit Margin
-114.77%
TTM Avg
-120.72%
3Y Avg
-96.63%
5Y Avg
-81.33%
Market Cap
$115.67M
Net Profit Margin
-175.78%
TTM Avg
-311.79%
3Y Avg
-369.50%
5Y Avg
-4193.27%
Market Cap
$122.43M
Net Profit Margin
-52.59%
TTM Avg
-29.17%
3Y Avg
-18.36%
5Y Avg
-9.63%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| LENZ Therapeutics, Inc. (LENZ) | $118.83M | -586.74% | -1091.31% | -92.15% | 0.00% |
| Tenaya Therapeutics, Inc. (TNYA)vs › | $118.59M | -7723.97% | 0.00% | 0.00% | 0.00% |
| Cibus, Inc. (CBUS)vs › | $119.84M | -2258.89% | -4695.34% | -8719.58% | -5863.11% |
| Spruce Biosciences, Inc. (SPRB)vs › | $117.76M | 0.00% | -539.97% | -388.73% | -259.15% |
| Seer, Inc. (SEER)vs › | $120.41M | -490.71% | -538.75% | -569.71% | -1398.02% |
| enGene Holdings Inc. (ENGN)vs › | $120.58M | 0.00% | 0.00% | 0.00% | 0.00% |
| MaxCyte, Inc. (MXCT)vs › | $116.76M | -114.77% | -120.72% | -96.63% | -81.33% |
| Foghorn Therapeutics Inc. (FHTX)vs › | $115.67M | -175.78% | -311.79% | -369.50% | -4193.27% |
| BGM Group Ltd. (BGM)vs › | $122.43M | -52.59% | -29.17% | -18.36% | -9.63% |
| Tonix Pharmaceuticals Holding Corp. (TNXP)vs › | $122.66M | -548.64% | -1117.24% | -934.06% | -622.71% |
Operating Margin
-477.5%
Net Profit Margin
-586.7%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | -581.81% |
| 2026-03-31 | -2182.43% |
| 2025-12-31 | -2260.45% |
| 2025-09-30 | -133.60% |
| 2025-06-30 | -298.24% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
